Valeant Calls Short Seller's Report Erroneous After Stock FallsBy
Drugmaker says no benefit when pharmacies hold inventory
Shares recover ground after falling as much as 40 percent
Valeant Pharmaceuticals International Inc. said a short seller’s allegation that it recorded fake sales to phony customers was “erroneous,” mounting a defense of its relationship with specialty pharmacies that failed to assuage investors.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.